Last reviewed · How we verify
Milrinone inhalation
At a glance
| Generic name | Milrinone inhalation |
|---|---|
| Also known as | primacor |
| Sponsor | Zagazig University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Inhaled Milrinone and Epoprostenol for the Prevention of Difficult Cardiac Pulmonary Bypass Separation (PHASE2)
- Treatment of Pulmonary Hypertension in High-risk Cardiac Surgery Patients Using Inhalational and Intravenous Agents (NA)
- Inhaled and Intravenous Milrinone in Patients With Severe Pulmonary Hypertension (PHASE4)
- Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery (PHASE2, PHASE3)
- Nebulized Inhaled Milrinone in a Hospitalized Advanced Heart Failure Population (PHASE1)
- Inhaled Milrinone Use in Patients Receiving HeartMate II LVAD: A Pilot Study (PHASE1)
- Milrinone Inhaled in Cardiac Surgery (PHASE2)
- Inhaled Milrinone in Cardiac Surgery (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |